Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices $1.5B Public Offering

NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it has priced its previously announced underwritten public offering. The company is selling 8,771,930 shares of common stock at $171 per share for expected gross proceeds of approximately $1.5 billion before the underwriting discount and expenses.

The company said it will use the proceeds from the offering to fund a portion of its $7.2 billion acquisition of contract development and manufacturing organization Patheon, including the repayment of indebtedness of Patheon to be assumed by Thermo Fisher. The company said it now expects to complete that deal around the end of the third quarter of 2017.

Thermo Fisher has also granted the underwriters a 30-day option to purchase up to an additional 1,315,789 shares. Goldman Sachs is acting as lead book-running manager for the offering. BofA Merrill Lynch and Citigroup are acting as joint book-running managers.

The issuance of the shares is expected to close on Aug. 11.

Thermo Fisher's shares dipped about 1 percent to $172.52 in morning trading on the New York Stock Exchange.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.